compounding pharmacies that make semaglutide | NextGenRx Compound Pharmacy Compounded Semaglutide: Patient Safety &

The North America obesity GLP-1 market size is estimated at USD 4.93 billion in 2025 and is projected to reach approximately USD 40.27 billion by 2035, with a 23.37% CAGR from 2026 to 2035

GLP-1s, on the other hand, are primarily associated with gastrointestinal side effects like nausea, diarrhea, and constipation

NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity

The burden and treatment of diabetes in elderly individuals in the US

In the pancreas, they stimulate glucose-dependent insulin secretion, meaning insulin is released only when blood glucose levels are elevated, which reduces the risk of hypoglycemia compared to some other diabetes medications

It is also approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver scarring as well as to lower the risk of heart attack, stroke, and death from heart disease in adults with heart disease and overweight or obesity